AZD8186 First Time In Patient Ascending Dose Study

NCT01884285 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Castrate-resistant Prostate Cancer CRPC
Squamous Non-Small Cell Lung Cancer sqNSCLC
Triple Negative Breast Cancer TNBC

Interventions

DRUG: Part A: AZD8186 monotherapy
DRUG: Part B: AZD8186 monotherapy
DRUG: Part C1: Abiraterone acetate combination with AZD8186
DRUG: Part D1: AZD2014 combination with AZD8186
DRUG: Part D2 AZD2014 combination with AZD8186
DRUG: Part C2: Abiraterone acetate combination with AZD8186

Sponsor

AstraZeneca